Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 35

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

454

WORD

251

HTML

3558

Figures (1-4)

182

Tables (1-4)

166

Sum=4611

Sep 21, 2014 (publication date) through Nov 13, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 21, 2014; 20(35): 12581-12587
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12581

Table 4 Comparison of clinical factors by location of major hepatocellular carcinoma

	Intrahepatic(n = 28)	Extrahepatic(n = 18)	P
Age (yr) (mean ± SD)	68.7 ± 8.5	73.6 ± 10.7	0.0500
Largest tumor (cm) [median (range)]	4.0 (1.5-15)	1.0 (0.0-5.0)	< 0.0001^a
Portal invasion (%)	64.2 (18/28)	5.7 (1/18)	< 0.0001^a
Sorafenib
800 mg	7	4	0.9769
400 mg	15	10
200 mg	6	4

SD: Standard deviation.

^aP < 0.05 vs control.

Citation: Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014; 20(35): 12581-12587
URL: https://www.wjgnet.com/1007-9327/full/v20/i35/12581.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i35.12581